Drug Discovery World

FEBRUARY 6, 2023

The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. We isolate antibodies from single human B cells using single cell genomics and assess, engineer, and advance these antibodies with other technologies. This has consequences for safety and efficacy.

Antibody 52

Antibody Immune Response Genome Genomics 52

pharmaphorum

OCTOBER 6, 2022

Disease modelling Gulf War Illness. In the mid-to-late 1990s, an unexplained illness began to emerge in army bases across the US. Symptoms and their severity ranged across individuals, and included fatigue, musculoskeletal pain, skin rashes, headaches, and gastrointestinal issues. Tinker, tailor, soldier, therapy.

In-Vivo 98

In-Vivo Research Genetics Drugs 98

The Pharma Data

JANUARY 12, 2021

KSQ is also eligible to receive tiered royalties on net sales of each approved product. KSQ will have the option to participate in cost/profit sharing on one of the two products based on the T-cell targets previously identified and validated by KSQ, in the U.S. sales for that product. sales for that product.

Development 52

Development Research In-Vivo Genome 52

XTalks

NOVEMBER 3, 2023

CRISPR works as genetic scissors to edit parts of the genome. The companies used data from the 1,000 Genomes Project but from that, only 61 datasets made the cut to encompass the ideal patient population. “I The CRISPR-Cas9 gene editing system was first discovered to be endogenous in bacteria.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

Drug Discovery World

SEPTEMBER 14, 2023

Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. Business updates Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational decline of $14.7 Vaccines were up 9.1%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

XTalks

APRIL 24, 2023

Dr. Eagleton recently spoke on a webinar with his colleagues from Medpace about lessons learned from successful approaches from rare disease and gene therapy product approvals. Last year, the FDA approved five novel cellular and gene therapy products with orphan drug designation.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

XTalks

AUGUST 5, 2020

Rosha Poudyal, PhD, Science and Technology Advisor at 10x Genomics, discussed some of the innovative single cell technology tools that the company is developing and their application in various research areas including oncology, infectious disease and immunology. The Power of Single Cell Technology. Feature barcoding using gel beads.

Gene Expression 112

Gene Expression Development RNA Drugs 112

pharmaphorum

JUNE 28, 2021

The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the body has yielded impressive results in patients with ATTR amyloidosis, a life-threatening rare disease. . — Eric Topol (@EricTopol) June 26, 2021. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 98

In-Vivo Gene Editing Trials Drugs 98

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T). About Kiromic.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

The Pharma Data

DECEMBER 10, 2020

.–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

APRIL 25, 2024

For drug discovery and development, cell lines allow researchers to test the efficacy of therapeutics before moving into in vivo studies. Moreso, CHO lines are well established within the industry and platforms are currently supported by a range of tools that can increase productivity and quality.

Development 59

Development Protein In-Vivo Life Science 59

Drug Discovery World

SEPTEMBER 6, 2022

With the sector looking strong it would be easy to think of the cell & gene sector as being resilient to challenge but this is never the case in pharma: fierce competition can result in fluctuating valuations for listed companies and the regulatory hurdles of pharma means that many companies won’t ever see their product reach the bedside. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

JANUARY 17, 2024

With oncology accounting for a third of pharma’s product pipeline, significant challenges include fierce competition, high research and development costs over, 10-15 years for clinical development, and pressures to rapidly meet the demand for new treatments 2-4.

Medicine 59

Medicine DNA Genome Genomics 59

The Pharma Data

JANUARY 10, 2021

Nasdaq: EDIT), a leading genome editing company, today announced the U.S. EDIT-301 is an experimental, ex vivo gene editing cell medicine in development for the treatment of sickle cell disease. CAMBRIDGE, Mass., 11, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc.

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 8, 2023

Marketing Product Manager, Product, NanoTemper Technologies. Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

NOVEMBER 22, 2020

Back in September, Vertex Pharmaceuticals and CRISPR Therapeutics – the company behind the CRISPR Cas-9 platform – announced that the European Medicines Agency (EMA) had granted Priority Medicines (PRIME) designation to CTX001, an investigational ex vivo CRISPR Cas-9 gene-edited therapy for the treatment of severe sickle cell disease.

Gene Editing 52

Gene Editing DNA Genome Genomics 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

NOVEMBER 15, 2022

We facilitate parallel DNA synthesis by coupling our chip technology with our re-engineered chemical method that can thermally control DNA synthesis at every single action site on the microchip,” says Dr Michael Daniels, Head of Product Management at Evonetix. . This way, we can separate erroneous sequences from accurate ones.

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

OCTOBER 17, 2022

By Dr Christof Gänzler, Product Marketing Biology at PerkinElmer Informatics. . The end game: reducing late-stage candidate failure and driving stronger innovation, productivity, and throughput. It’s a centuries-old truism: the fastest runner doesn’t always win the race. It takes more than speed to advance and maintain performance.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

OCTOBER 14, 2020

VBL has recently demonstrated ex-vivo activity of anti-MOSPD2 antibodies in patients with relapsing-remitting and progressive multiple sclerosis (MS), as well as in animal models of rheumatoid arthritis (RA), nonalcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD). 1. -- -->. -- [if lte IE 8]--> .

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52